Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study
Johan Sundström(Uppsala University), Navdeep Tangri(Orthopaedic Innovation Centre), Gijs VanPottelbergh, Johan Bodegård(Statistics Norway), Avraham Karasik(Maccabi Institute for Health Services Research), Manish M. Sood(Ottawa Hospital), Marc Vervloet(Radboud University Nijmegen), Patrick B. Mark(Queen Elizabeth University Hospital), Andreas Bollmann(Helios Park-Klinikum Leipzig), Tiago Taveira‐Gomes(Fernando Pessoa University), Marcus Thuresson(Statisticon (Sweden)), Levy Jäger(University of Zurich), Manuel Botana(Hospital Universitario Lucus Augusti), Kåre I. Birkeland(Oslo University Hospital)
Cited by 315
Related Papers
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity
|European Heart Journal|2005|1.1k
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
|Kidney International|2017|998
Chronic Kidney Disease and Coronary Artery Disease
|Journal of the American College of Cardiology|2019|716